Cellceutix’ Kevetrin gets Rare Pediatric Disease designation from FDA

US biotech firm Cellceutix Corp (OTCQB: CTIX) revealed that the US Food and Drug Administration has granted Rare Pediatric Disease designation for its Kevetrin (thioureidobutyronitrile) for the treatment of retinoblastoma, a rare form of eye cancer that begins in the retina, the light sensitive nerve tissue that lines the back of the eye.

Retinoblastoma is most generally found in children, usually before the age of three, and rarely found in adults. It is sight threatening and potentially fatal if not diagnosed early. The rare pediatric disease designation supplements the Orphan Drug Designation granted by the FDA to Kevetrin for retinoblastoma, as announced on November 23, 2015.